Phase III study of ixazomib in multiple myeloma fails to meet primary endpoint

In the TOURMALINE-MM2 clinical trial, the addition of ixazomib to lenalidomide and dexamethasone did not result in a statistically significant improvement in progression-free survival in patients with newly diagnosed multiple myeloma.

Source:

Biospace Inc.